Depression News and Research

Latest Depression News and Research

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

New e-SMART-HD program helps improve doctor-patient communications

While many young adults will share the details of their daily lives with friends on Facebook, communicating with their doctors about mental illness is another story. E-SMART-MH, developed at Case Western Reserve University, might improve those communications.

29 Oct 2010

New eight-month pilot program to advance standards of care for people with schizophrenia

The National Council for Community Behavioral Healthcare (National Council) today announced a new eight-month pilot program designed to advance standards of care for people living with schizophrenia. This initiative at 10 community behavioral health organizations nationwide is designed to improve the daily functioning of people with schizophrenia and raise expectations for what is achievable.

29 Oct 2010

Mary Ann Liebert launches Brain Connectivity journal

Mary Ann Liebert, Inc. announces the release of a new peer-reviewed journal in an expanding area of systems neuroscience, Brain Connectivity. This timely new journal is positioned to become the premier source of cutting-edge basic and clinical neuroscience research aimed at better understanding of structural and functional connections in the brain and how these connections are altered by neurological disorders.

29 Oct 2010

Low household income associated with chronic migraine

New data presented today at The 2010 European Headache and Migraine Trust International Congress (EHMTIC) shows that persons with chronic migraine (headache on greater than or equal to 15 days per month) are much more likely to have annual household incomes below $30,000 than those with episodic migraine (headache on < 15 days per month).

29 Oct 2010

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

The first national outcome-based contract between a pharmaceutical company and a pharmacy benefit management company resulted in an increase in the number of people with type 2 diabetes who were able to control their blood sugar levels by taking their medications appropriately.

29 Oct 2010

Long hours and nights on call lead to surgeon distress

Just as with everyone else perhaps, the more hours surgeons work, and the more nights they spend on call each week, the more likely they are to face burn-out, depression, dissatisfaction with their careers and serious work-home conflicts, according to a major new study led by Johns Hopkins and Mayo Clinic researchers.

29 Oct 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

World's largest research initiative to mutate all mouse genes

The world's largest research initiative to mutate all mouse genes is now able to reach the summit because the ambitious EUCOMMTOOLS project started on October 1, 2010. This project is being coordinated by Helmholtz Zentrum München and will finalize the groundwork for the analysis of all mouse gene functions. The findings will contribute to a better understanding of the pathogenesis of widespread diseases such as Alzheimer's, depression, diabetes, chronic lung diseases or cancer.

28 Oct 2010

Evotec grants Jingxin Pharma rights to develop, market EVT 201 insomnia drug candidate in China

Evotec AG today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd for EVT 201, a novel potential treatment for insomnia. The agreement grants Jingxin Pharma exclusive rights to develop and market the drug candidate in China. In return, Evotec will receive a small upfront payment, together with commercial milestones and significant royalties.

28 Oct 2010

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante, Inc., the leader in centralized expert evaluation of central nervous system (CNS) disorders, and Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, announced that Rexahn will use MedAvante 's Remote Centralized Ratings™ in their randomized, double-blind, placebo-controlled Phase 2b clinical study assessing the efficacy of Serdaxin® in patients with major depressive disorder (MDD).

27 Oct 2010

New intervention strategies help manage depression

In the 15 minutes a primary care doctor typically has with a patient, she's expected to diagnose the current ailment, help manage ongoing health issues and provide preventive care. In this setting, confronting all but the most obvious and immediate mental health needs of patients is an ongoing challenge.

27 Oct 2010

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist.

27 Oct 2010

Evotec, Apeiron Biologics enter collaboration

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Further projects will be evaluated to potentially expand this cooperation in due course.

27 Oct 2010

Study finds prevalence of cognitive impairment in older adults with severe sepsis

Older adults who survived severe sepsis were more likely to develop substantial cognitive impairment and functional disability, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Neurologix holds license for gene therapy to treat severe depression

Neurologix, Inc. today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment option for people who suffer from severe depression.

26 Oct 2010

Survey highlights emotional impact of psoriasis on school children

Almost half of children with psoriasis surveyed by the National Psoriasis Foundation report being bullied at least once in the last six months. The Psoriasis Foundation surveyed parents of kids with psoriatic disease and found that 44 percent of children have been bullied by their peers, and 38 percent of kids say the abuse was a direct result of their disease.

26 Oct 2010

Paramedics at risk of stress, anxiety and depression: Study

According to the latest research paramedics are at a high risk of stress and depression. The Victorian study showed that around ten per cent of paramedics were found to have severe or extremely severe depression, while 40 per cent reported feeling the effects of stress. Nearly 25% were also found to suffer an “above normal degree of anxiety”.

25 Oct 2010

Motherhood helps women grow their grey matter: Study

According to the latest research motherhood helps women grow their grey matter. The study was conducted by scientists at the National Institute of Mental Health in Maryland and it showed that the brains of new mothers substantially gained in nerve cells while they coped with the steep learning curve of dealing with a newborn. Also in a bizarre way, mothers who ‘gushed’ the most about their babies showed the greatest growth in key parts of the brain.

24 Oct 2010

Researchers suggest gene therapy may treat patients with major depression

In a report published in the Oct. 20 issue of Science Translational Medicine, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say animal and human data suggest gene therapy to the brain may be able to treat patients with major depression who do not respond to traditional drug treatment.

22 Oct 2010